Tathagat Narula

Tathagat Narula

Auto-generated profile, based on publicly available information

Tathagat Narula

Department of Transplantation, Mayo Clinic, Jacksonville, Florida, USA, mayo.edu

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 January 2023 in European Heart Journal - Digital Health
Verified
Journal Article
Open access
PDF file
DADemilade Adedinsewo
Demilade Adedinsewo
HHHeather D Hardway
Heather D Hardway
AMAndrea Carolina Morales-Lara
Andrea Carolina Morales-Lara
MWMikolaj A Wieczorek
Mikolaj A Wieczorek
PJPatrick W Johnson
Patrick W Johnson
MYMohamad Yamani
Mohamad Yamani
Aims: Current non-invasive screening methods for cardiac allograft rejection have shown limited discrimination and are yet to be broadly integrated into heart transplant care. Given electrocardiogram (ECG) changes have been reported with severe cardiac allograft rejection, this study aimed to develop a deep-learning model, a form of artificial intelligence, to detect allograft rejection using the 12-lead ECG (AI-ECG). Methods and results: Heart transplant recipients were identified across three Mayo Clinic sites between 1998 and 2021. Twelve-lead digital ECG data and endomyocardial biopsy results were extracted from medical records. Allograft rejection was defined as moderate or severe acute cellular rejection (ACR) based on International Society for Heart and Lung Transplantation guidelines. The extracted data (7590 unique ECG-biopsy pairs, belonging to 1427 patients) was partitioned into training (80%), validation (10%), and test sets (10%) such that each patient was included in only one partition. Model performance metrics were based on the test set (n = 140 patients; 758 ECG-biopsy pairs). The AI-ECG detected ACR with an area under the receiver operating curve (AUC) of 0.84 [95% confidence interval (CI): 0.78–0.90] and 95% (19/20; 95% CI: 75–100%) sensitivity. A prospective proof-of-concept screening study (n = 56; 97 ECG-biopsy pairs) showed the AI-ECG detected ACR with AUC = 0.78 (95% CI: 0.61–0.96) and 100% (2/2; 95% CI: 16–100%) sensitivity. Conclusion: An AI-ECG model is effective for detection of moderate-to-severe ACR in heart transplant recipients. Our findings could improve transplant care by providing a rapid, non-invasive, and potentially remote screening option for cardiac allograft function.

21 December 2023 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
QXQingyong Xu
Qingyong Xu
MEMohamed Elrefaei
Mohamed Elrefaei
JTJean-Luc Taupin
Jean-Luc Taupin
KHKelley M.K. Hitchman
Kelley M.K. Hitchman
SHSteven Hiho
Steven Hiho
ARAntoine Roux
Antoine Roux

1 October 2015 in American Journal of Respiratory Cell and Molecular Biology
Verified
Journal Article
Closed access
TNTathagat Narula
Tathagat Narula
BDBennett P. Deboisblanc
Bennett P. Deboisblanc
Ghrelin, a recently described peptide, has attracted significant attention in recent years, primarily in the context of its endocrine- and appetite-regulating effects. The versatility of this peptide is manifested in a rapidly expanding body of literature highlighting its nonendocrine functions. This review summarizes the available data on the immunomodulatory as well as the non–immune-mediated effects of ghrelin that form the scientific basis of its role in critical illness.

26 July 2022 in Stem Cells Translational Medicine
Verified
Journal Article
Open access
PDF file
DEDavid Brett Erasmus
David Brett Erasmus
NDNisha Durand
Nisha Durand
FAFrancisco A Alvarez
Francisco A Alvarez
TNTathagat Narula
Tathagat Narula
DHDavid O Hodge
David O Hodge
AZAbba Zubair
Abba Zubair
We have previously shown bone marrow-derived mesenchymal stem cells (MSCs) may shift immune responses toward anti-inflammatory pathways and stabilize the course of obstructive chronic lung allograft syndrome (o-CLAD) after lung transplantation. In this study, we measured the response of lower dose infusions. We infused low-dose MSCs intravenously in 13 patients who had developed moderate-to-severe o-CLAD. Three had previously received an infusion of MSCs from a different donor and were re-dosed at 1 × 106 MSC/kg, while 5 received a first dose at 1 × 106 MSC/kg and five received an even lower dose at 0.5 × 106 MSC/kg. We recorded pulmonary function tests before and after infusion, and patients were followed clinically for 12 months. Infusions were well tolerated, and no significant adverse events were recorded in the first 30 days. There was significant decline (mean ± SD) in forced vital capacity (FVC) (3.49 ± 1.03 vs 3.18 ± 0.94 L, P = .03) and forced expiratory volume in 1 second (FEV1) (2.28 ± 0.86 vs 1.77 ± 0.49 L, P = .04) over the year preceding infusion. FVC (3.18 ± 0.94 vs 3.46 ± 0.99 L, P = .53) and FEV1 was not significantly changed (1.77 ± 0.49 vs 1.88 ± 0.75, P = .72) when comparing values immediately prior to infusion to those obtained 1 year after infusion, indicating a possible stabilizing effect on lung function decline due to o-CLAD. Intravenous infusions of bone marrow-derived MSCs are well tolerated in lung transplant recipients with moderate-to-severe CLAD. Low-dose MSCs appear to slow progression of CLAD in some patients. Forced expiratory volume in 1 second (FEV1 in liters) was measured before and after low-dose mesenchymal stem cell infusions (0.5 or 1 million cells/kg on day 0) in lung transplant recipients with moderate to severe chronic lung allograft dysfunction. Infusions were well tolerated and showed a stabilizing effect on FEV1 decline when measured 1 year after infusion (P = .72)

1 March 2020 in Transplantation
Verified
Journal Article
Closed access
MKMinkyung Kwon
Minkyung Kwon
FAFrancisco Alvarez
Francisco Alvarez
PFPablo Moreno Franco
Pablo Moreno Franco
APAlicia PharmD Patel
Alicia PharmD Patel
JCJuan M. Canabal
Juan M. Canabal
TNTathagat Mbbs Narula
Tathagat Mbbs Narula

26 February 2023 in Transplantation Proceedings
Verified
Journal Article
Closed access
TNTathagat Narula
Tathagat Narula
AMArcher K. Martin
Archer K. Martin
AAAbuzar A. Asif
Abuzar A. Asif
AFAshley V. Fritz
Ashley V. Fritz
ZLZhuo Li
Zhuo Li
MTMathew Thomas
Mathew Thomas